세계의 원료의약품(API) 시장(2025-2035년) : 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측

Active Pharmaceutical Ingredients (API) Market - Scope of Report

TMR's report on the global active pharmaceutical ingredients (API) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global active pharmaceutical ingredients (API) market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global active pharmaceutical ingredients (API) market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the active pharmaceutical ingredients (API) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global active pharmaceutical ingredients (API) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global active pharmaceutical ingredients (API) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global active pharmaceutical ingredients (API) market.

The report delves into the competitive landscape of the global active pharmaceutical ingredients (API) market. Key players operating in the global active pharmaceutical ingredients (API) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global active pharmaceutical ingredients (API) market profiled in this report.

Key Questions Answered in Global active pharmaceutical ingredients (API) Market Report:

• What is the sales/revenue generated by active pharmaceutical ingredients (API) across all regions during the forecast period?
• What are the opportunities in the global active pharmaceutical ingredients (API) market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Active Pharmaceutical Ingredients (API) Market - Research Objectives and Research Approach

The comprehensive report on the global active pharmaceutical ingredients (API) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global active pharmaceutical ingredients (API) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global active pharmaceutical ingredients (API) market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Active Pharmaceutical Ingredients (API) Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure Data across Key Countries
• 5.2. Supply Chain Analysis
• 5.3. PESTLE Analysis
• 5.4. PORTER's Five Forces Analysis
• 5.5. Regulatory Landscape across Key Regions / Countries
• 5.6. Go-to-Market Strategy for New Market Entrants across Key Regions / Countries
• 5.7. Pricing Analysis
• 5.8. Key Industry Events
• 5.9. Distributors Landscape
• 5.10. Supply Chain Analysis

6. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Molecule Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 6.3.1. Acetaminophen
  • 6.3.2. Naproxen
  • 6.3.3. Furosemide
  • 6.3.4. Nitrofurantoin
  • 6.3.5. Sulfadoxine
  • 6.3.6. Pyrimethamine
  • 6.3.7. Amodiaquine
  • 6.3.8. Atazanavir Sulfate
  • 6.3.9. Nimesulide
  • 6.3.10. Ciprofloxacin
  • 6.3.11. Sulfadoxine
  • 6.3.12. Piperaquine Phosphate
  • 6.3.13. Sotalol
  • 6.3.14. Levetiracetam
  • 6.3.15. Diclofenac
  • 6.3.16. Azithromycin
  • 6.3.17. Others
• 6.4. Market Attractiveness By Molecule Type

7. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Production Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Production Type, 2020 to 2035
  • 7.3.1. Captive/In House
  • 7.3.2. Outsourcing
• 7.4. Market Attractiveness By Production Type

8. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Product Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Product Type, 2020 to 2035
  • 8.3.1. Low Potent API
  • 8.3.2. High Potent API
• 8.4. Market Attractiveness By Product Type

9. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By API Type

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By API Type, 2020 to 2035
  • 9.3.1. Synthetic
  • 9.3.2. Natural
• 9.4. Market Attractiveness By API Type

10. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Scale

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Scale, 2020 to 2035
  • 10.3.1. Pilot
  • 10.3.2. Large
• 10.4. Market Attractiveness By Scale

11. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Application

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By Application, 2020 to 2035
  • 11.3.1. Commercial
  • 11.3.2. Research
• 11.4. Market Attractiveness By Application

12. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By End-user

• 12.1. Introduction & Definition
• 12.2. Key Findings / Developments
• 12.3. Market Value Forecast By Application, 2020 to 2035
  • 12.3.1. Pharmaceutical Companies
  • 12.3.2. Biotechnological Companies
  • 12.3.3. Contract Manufacturing Organisation's (CMO's)
  • 12.3.4. Others
• 12.4. Market Attractiveness By End User

13. Global Active Pharmaceutical Ingredients (API) Market Analysis and Forecasts, By Region

• 13.1. Key Findings
• 13.2. Market Value Forecast By Region
  • 13.2.1. North America
  • 13.2.2. Europe
  • 13.2.3. Asia Pacific
  • 13.2.4. Latin America
  • 13.2.5. Middle East & Africa
• 13.3. Market Attractiveness By Region

14. North America Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 14.2.1. Acetaminophen
  • 14.2.2. Naproxen
  • 14.2.3. Furosemide
  • 14.2.4. Nitrofurantoin
  • 14.2.5. Sulfadoxine
  • 14.2.6. Pyrimethamine
  • 14.2.7. Amodiaquine
  • 14.2.8. Atazanavir Sulfate
  • 14.2.9. Nimesulide
  • 14.2.10. Ciprofloxacin
  • 14.2.11. Sulfadoxine
  • 14.2.12. Piperaquine Phosphate
  • 14.2.13. Sotalol
  • 14.2.14. Levetiracetam
  • 14.2.15. Diclofenac
  • 14.2.16. Azithromycin
  • 14.2.17. Others
• 14.3. Market Value Forecast By Production Type, 2020 to 2035
  • 14.3.1. Captive/In House
  • 14.3.2. Outsourcing
• 14.4. Market Value Forecast By Product Type, 2020 to 2035
  • 14.4.1. Low Potent API
  • 14.4.2. High Potent API
• 14.5. Market Value Forecast By API Type, 2020 to 2035
  • 14.5.1. Synthetic
  • 14.5.2. Natural
• 14.6. Market Value Forecast By Scale, 2020 to 2035
  • 14.6.1. Pilot
  • 14.6.2. Large
• 14.7. Market Value Forecast By Application, 2020 to 2035
  • 14.7.1. Commercial
  • 14.7.2. Research
• 14.8. Market Value Forecast By End-user, 2020 to 2035
  • 14.8.1. Pharmaceutical Companies
  • 14.8.2. Biotechnological Companies
  • 14.8.3. Contract Manufacturing Organization's (CMO)
  • 14.8.4. Others
• 14.9. Market Value Forecast By Country, 2020 to 2035
  • 14.9.1. U.S.
  • 14.9.2. Canada
• 14.10. Market Attractiveness Analysis
  • 14.10.1. By Molecule Type
  • 14.10.2. By Production Type
  • 14.10.3. By Product Type
  • 14.10.4. By API Type
  • 14.10.5. By Scale
  • 14.10.6. By Application
  • 14.10.7. By End-user
  • 14.10.8. By Country

15. Europe Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 15.2.1. Acetaminophen
  • 15.2.2. Naproxen
  • 15.2.3. Furosemide
  • 15.2.4. Nitrofurantoin
  • 15.2.5. Sulfadoxine
  • 15.2.6. Pyrimethamine
  • 15.2.7. Amodiaquine
  • 15.2.8. Atazanavir Sulfate
  • 15.2.9. Nimesulide
  • 15.2.10. Ciprofloxacin
  • 15.2.11. Sulfadoxine
  • 15.2.12. Piperaquine Phosphate
  • 15.2.13. Sotalol
  • 15.2.14. Levetiracetam
  • 15.2.15. Diclofenac
  • 15.2.16. Azithromycin
  • 15.2.17. Others
• 15.3. Market Value Forecast By Production Type, 2020 to 2035
  • 15.3.1. Captive/In House
  • 15.3.2. Outsourcing
• 15.4. Market Value Forecast By Product Type, 2020 to 2035
  • 15.4.1. Low Potent API
  • 15.4.2. High Potent API
• 15.5. Market Value Forecast By API Type, 2020 to 2035
  • 15.5.1. Synthetic
  • 15.5.2. Natural
• 15.6. Market Value Forecast By Scale, 2020 to 2035
  • 15.6.1. Pilot
  • 15.6.2. Large
• 15.7. Market Value Forecast By Application, 2020 to 2035
  • 15.7.1. Commercial
  • 15.7.2. Research
• 15.8. Market Value Forecast By End-user, 2020 to 2035
  • 15.8.1. Pharmaceutical Companies
  • 15.8.2. Biotechnological Companies
  • 15.8.3. Contract Manufacturing Organization's (CMO)
  • 15.8.4. Others
• 15.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 15.9.1. Germany
  • 15.9.2. U.K.
  • 15.9.3. France
  • 15.9.4. Spain
  • 15.9.5. Italy
  • 15.9.6. Switzerland
  • 15.9.7. The Netherlands
  • 15.9.8. Rest of Europe
• 15.10. Market Attractiveness Analysis
  • 15.10.1. By Molecule Type
  • 15.10.2. By Production Type
  • 15.10.3. By Product Type
  • 15.10.4. By API Type
  • 15.10.5. By Scale
  • 15.10.6. By Application
  • 15.10.7. By End-user
  • 15.10.8. By Country/Sub-region

16. Asia Pacific Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 16.2.1. Acetaminophen
  • 16.2.2. Naproxen
  • 16.2.3. Furosemide
  • 16.2.4. Nitrofurantoin
  • 16.2.5. Sulfadoxine
  • 16.2.6. Pyrimethamine
  • 16.2.7. Amodiaquine
  • 16.2.8. Atazanavir Sulfate
  • 16.2.9. Nimesulide
  • 16.2.10. Ciprofloxacin
  • 16.2.11. Sulfadoxine
  • 16.2.12. Piperaquine Phosphate
  • 16.2.13. Sotalol
  • 16.2.14. Levetiracetam
  • 16.2.15. Diclofenac
  • 16.2.16. Azithromycin
  • 16.2.17. Others
• 16.3. Market Value Forecast By Production Type, 2020 to 2035
  • 16.3.1. Captive/In House
  • 16.3.2. Outsourcing
• 16.4. Market Value Forecast By Product Type, 2020 to 2035
  • 16.4.1. Low Potent API
  • 16.4.2. High Potent API
• 16.5. Market Value Forecast By API Type, 2020 to 2035
  • 16.5.1. Synthetic
  • 16.5.2. Natural
• 16.6. Market Value Forecast By Scale, 2020 to 2035
  • 16.6.1. Pilot
  • 16.6.2. Large
• 16.7. Market Value Forecast By Application, 2020 to 2035
  • 16.7.1. Commercial
  • 16.7.2. Research
• 16.8. Market Value Forecast By End-user, 2020 to 2035
  • 16.8.1. Pharmaceutical Companies
  • 16.8.2. Biotechnological Companies
  • 16.8.3. Contract Manufacturing Organization's (CMO)
  • 16.8.4. Others
• 16.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 16.9.1. China
  • 16.9.2. Japan
  • 16.9.3. India
  • 16.9.4. Australia & New Zealand
  • 16.9.5. South Korea
  • 16.9.6. Rest of Asia Pacific
• 16.10. Market Attractiveness Analysis
  • 16.10.1. By Molecule Type
  • 16.10.2. By Production Type
  • 16.10.3. By Product Type
  • 16.10.4. By API Type
  • 16.10.5. By Scale
  • 16.10.6. By Application
  • 16.10.7. By End-user
  • 16.10.8. By Country/Sub-region

17. Latin America Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 17.2.1. Acetaminophen
  • 17.2.2. Naproxen
  • 17.2.3. Furosemide
  • 17.2.4. Nitrofurantoin
  • 17.2.5. Sulfadoxine
  • 17.2.6. Pyrimethamine
  • 17.2.7. Amodiaquine
  • 17.2.8. Atazanavir Sulfate
  • 17.2.9. Nimesulide
  • 17.2.10. Ciprofloxacin
  • 17.2.11. Sulfadoxine
  • 17.2.12. Piperaquine Phosphate
  • 17.2.13. Sotalol
  • 17.2.14. Levetiracetam
  • 17.2.15. Diclofenac
  • 17.2.16. Azithromycin
  • 17.2.17. Others
• 17.3. Market Value Forecast By Production Type, 2020 to 2035
  • 17.3.1. Captive/In House
  • 17.3.2. Outsourcing
• 17.4. Market Value Forecast By Product Type, 2020 to 2035
  • 17.4.1. Low Potent API
  • 17.4.2. High Potent API
• 17.5. Market Value Forecast By API Type, 2020 to 2035
  • 17.5.1. Synthetic
  • 17.5.2. Natural
• 17.6. Market Value Forecast By Scale, 2020 to 2035
  • 17.6.1. Pilot
  • 17.6.2. Large
• 17.7. Market Value Forecast By Application, 2020 to 2035
  • 17.7.1. Commercial
  • 17.7.2. Research
• 17.8. Market Value Forecast By End-user, 2020 to 2035
  • 17.8.1. Pharmaceutical Companies
  • 17.8.2. Biotechnological Companies
  • 17.8.3. Contract Manufacturing Organization's (CMO)
  • 17.8.4. Others
• 17.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 17.9.1. Brazil
  • 17.9.2. Mexico
  • 17.9.3. Argentina
  • 17.9.4. Rest of Latin America
• 17.10. Market Attractiveness Analysis
  • 17.10.1. By Molecule Type
  • 17.10.2. By Production Type
  • 17.10.3. By Product Type
  • 17.10.4. By API Type
  • 17.10.5. By Scale
  • 17.10.6. By Application
  • 17.10.7. By Application
  • 17.10.8. By Country/Sub-region

18. Middle East & Africa Active Pharmaceutical Ingredients (API) Market Analysis and Forecast

• 18.1. Introduction
  • 18.1.1. Key Findings
• 18.2. Market Value and Volume Forecast By Molecule Type, 2020 to 2035
  • 18.2.1. Acetaminophen
  • 18.2.2. Naproxen
  • 18.2.3. Furosemide
  • 18.2.4. Nitrofurantoin
  • 18.2.5. Sulfadoxine
  • 18.2.6. Pyrimethamine
  • 18.2.7. Amodiaquine
  • 18.2.8. Atazanavir Sulfate
  • 18.2.9. Nimesulide
  • 18.2.10. Ciprofloxacin
  • 18.2.11. Sulfadoxine
  • 18.2.12. Piperaquine Phosphate
  • 18.2.13. Sotalol
  • 18.2.14. Levetiracetam
  • 18.2.15. Diclofenac
  • 18.2.16. Azithromycin
  • 18.2.17. Others
• 18.3. Market Value Forecast By Production Type, 2020 to 2035
  • 18.3.1. Captive/In House
  • 18.3.2. Outsourcing
• 18.4. Market Value Forecast By Product Type, 2020 to 2035
  • 18.4.1. Low Potent API
  • 18.4.2. High Potent API
• 18.5. Market Value Forecast By API Type, 2020 to 2035
  • 18.5.1. Synthetic
  • 18.5.2. Natural
• 18.6. Market Value Forecast By Scale, 2020 to 2035
  • 18.6.1. Pilot
  • 18.6.2. Large
• 18.7. Market Value Forecast By Application, 2020 to 2035
  • 18.7.1. Commercial
  • 18.7.2. Research
• 18.8. Market Value Forecast By End-user, 2020 to 2035
  • 18.8.1. Pharmaceutical Companies
  • 18.8.2. Biotechnological Companies
  • 18.8.3. Contract Manufacturing Organization's (CMO)
  • 18.8.4. Others
• 18.9. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 18.9.1. GCC Countries
  • 18.9.2. South Africa
  • 18.9.3. Rest of Middle East & Africa
• 18.10. Market Attractiveness Analysis
  • 18.10.1. By Molecule Type
  • 18.10.2. By Production Type
  • 18.10.3. By Product Type
  • 18.10.4. By API Type
  • 18.10.5. By Scale
  • 18.10.6. By Application
  • 18.10.7. By End-user
  • 18.10.8. By Country/Sub-region

19. Competition Landscape

• 19.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 19.2. Market Share Analysis By Company (2024)
• 19.3. Company Profiles
  • 19.3.1. Merck KGaA
    • 19.3.1.1. Company Overview
    • 19.3.1.2. Financial Overview
    • 19.3.1.3. Product Portfolio
    • 19.3.1.4. Business Strategies
    • 19.3.1.5. Recent Developments
  • 19.3.2. Teva Pharmaceutical Industries Ltd.
    • 19.3.2.1. Company Overview
    • 19.3.2.2. Financial Overview
    • 19.3.2.3. Product Portfolio
    • 19.3.2.4. Business Strategies
    • 19.3.2.5. Recent Developments
  • 19.3.3. Pfizer Inc
    • 19.3.3.1. Company Overview
    • 19.3.3.2. Financial Overview
    • 19.3.3.3. Product Portfolio
    • 19.3.3.4. Business Strategies
    • 19.3.3.5. Recent Developments
  • 19.3.4. Mangalam Drugs & Organics Limited
    • 19.3.4.1. Company Overview
    • 19.3.4.2. Financial Overview
    • 19.3.4.3. Product Portfolio
    • 19.3.4.4. Business Strategies
    • 19.3.4.5. Recent Developments
  • 19.3.5. Viatris Inc.
    • 19.3.5.1. Company Overview
    • 19.3.5.2. Financial Overview
    • 19.3.5.3. Product Portfolio
    • 19.3.5.4. Business Strategies
    • 19.3.5.5. Recent Developments
  • 19.3.6. Lonza.
    • 19.3.6.1. Company Overview
    • 19.3.6.2. Financial Overview
    • 19.3.6.3. Product Portfolio
    • 19.3.6.4. Business Strategies
    • 19.3.6.5. Recent Developments
  • 19.3.7. Piramal Pharma Solutions
    • 19.3.7.1. Company Overview
    • 19.3.7.2. Financial Overview
    • 19.3.7.3. Product Portfolio
    • 19.3.7.4. Business Strategies
    • 19.3.7.5. Recent Developments
  • 19.3.8. HISUN USA, inc.
    • 19.3.8.1. Company Overview
    • 19.3.8.2. Financial Overview
    • 19.3.8.3. Product Portfolio
    • 19.3.8.4. Business Strategies
    • 19.3.8.5. Recent Developments
  • 19.3.9. Ipca Laboratories Ltd
    • 19.3.9.1. Company Overview
    • 19.3.9.2. Financial Overview
    • 19.3.9.3. Product Portfolio
    • 19.3.9.4. Business Strategies
    • 19.3.9.5. Recent Developments
  • 19.3.10. AbbVie Inc.
    • 19.3.10.1. Company Overview
    • 19.3.10.2. Financial Overview
    • 19.3.10.3. Product Portfolio
    • 19.3.10.4. Business Strategies
    • 19.3.10.5. Recent Developments
  • 19.3.11. Alembic Pharmaceuticals Limited
    • 19.3.11.1. Company Overview
    • 19.3.11.2. Financial Overview
    • 19.3.11.3. Product Portfolio
    • 19.3.11.4. Business Strategies
    • 19.3.11.5. Recent Developments
  • 19.3.12. Biocon
    • 19.3.12.1. Company Overview
    • 19.3.12.2. Financial Overview
    • 19.3.12.3. Product Portfolio
    • 19.3.12.4. Business Strategies
    • 19.3.12.5. Recent Developments
  • 19.3.13. Boehringer Ingelheim
    • 19.3.13.1. Company Overview
    • 19.3.13.2. Financial Overview
    • 19.3.13.3. Product Portfolio
    • 19.3.13.4. Business Strategies
    • 19.3.13.5. Recent Developments
  • 19.3.14. Cambrex Corporation.
    • 19.3.14.1. Company Overview
    • 19.3.14.2. Financial Overview
    • 19.3.14.3. Product Portfolio
    • 19.3.14.4. Business Strategies
    • 19.3.14.5. Recent Developments
  • 19.3.15. Dr. Reddy's Laboratories Ltd.
    • 19.3.15.1. Company Overview
    • 19.3.15.2. Financial Overview
    • 19.3.15.3. Product Portfolio
    • 19.3.15.4. Business Strategies
    • 19.3.15.5. Recent Developments
  • 19.3.16. Sun Pharmaceutical Industries Ltd.
    • 19.3.16.1. Company Overview
    • 19.3.16.2. Financial Overview
    • 19.3.16.3. Product Portfolio
    • 19.3.16.4. Business Strategies
    • 19.3.16.5. Recent Developments
  • 19.3.17. Cipla.
    • 19.3.17.1. Company Overview
    • 19.3.17.2. Financial Overview
    • 19.3.17.3. Product Portfolio
    • 19.3.17.4. Business Strategies
    • 19.3.17.5. Recent Developments